Executive Summary—Key Findings

Executive Summary—Key Findings (continued)

Haemophilia Drugs Market—Game-changing Strategies

Key Merger, Acquisition, and Partnership Assessment

Key Merger, Acquisition, and Partnership Assessment (continued)

Methodology and Scope

Introduction

Introduction (continued)

Classification of Haemophilia

Treatment Guidelines for Haemophilia Therapy—Prophylactic or On-demand

Market Overview—Segmentation

Market Overview—Segmentation (continued)

Haemophilia—Prevalence and Incidence

Haemophilia—Global Prevalence and Treatment Rates

Forecast Assumptions and Definitions

Haemophilia Therapeutics Market—Revenue Forecast

Revenue Forecast Discussion

Revenue Forecast Discussion (continued)

Increasing Use of Recombinant and Prophylactic Treatment

Variation in Adoption of Prophylactic Therapy by Region

Annual Switching Rates in Haemophilia

Global Haemophilia A and vWD Therapeutics Market Revenue Forecast

Revenue Forecast Discussion

Revenue Forecast Discussion (continued)

Haemophilia B Therapeutics Market—Revenue Forecast

Revenue Forecast Discussion

Revenue Forecast Discussion (continued)

Inhibitors (Bypassing Agents) Market—Revenue Forecast

Revenue Forecast Discussion

Revenue Forecast Discussion (continued)

Product Analysis—F VIII (Haemophilia A) and FVIII/vWF (vWD)

Product Analysis—F VIII (Haemophilia A) and FVIII/vWF (vWD) (continued)

Product Analysis—F VIII (Haemophilia A) and FVIII/vWF (vWD) (continued)

Product Analysis—F VIII (Haemophilia A) and FVIII/vWF (vWD) (continued)

Product Analysis—Factor IX (Haemophilia B)

Product Analysis—Factor IX (Haemophilia B) (continued)

Product Analysis—Factor VIIa (Inhibitors)

Haemophilia Drugs—Competitive Landscape of Products in Development

Haematological Drugs—Pipeline Analysis

Pipeline Analysis—F VIII (Haemophilia A) and FVIII/VWF (VWD)

Pipeline Analysis—F IX (Haemophilia B)

Pipeline Analysis—F VIIa (Inhibitors)

Haemophilia Therapeutics Market—Major Ongoing/Recently Completed Clinical Trials

Haemophilia Therapeutics Market—Major Ongoing/Recently Completed Clinical Trials (continued)

Haemophilia Therapeutics Market—Major Ongoing/Recently Completed Clinical Trials (continued)

Eloctate—Biogen Idec/SOBI

NovoEight (Turoctocog alfa)—Novo Nordisk

BAX 111—Baxter

BAX 855—Baxter

BAY81-8973—Bayer

Nuwiq/Human-cl rhFVIII (simotocog alfa)—Octapharma

BAY94-9027—Bayer

N8-GP (turoctocog alfa pegol)—Novo Nordisk

rVIII-Single Chain—CSL Behring

Alprolix—Biogen Idec/SOBI

Rixubis—Baxter

rIX-FP—CSL Behring

IB1001—Cangene (Emergent Biosolutions)

N9-GP (nonacog beta pegol)—Novo Nordisk

Obizur—Baxter

BAX 817—Baxter

LR769—rEVO Biologics/LFB

Novel Technologies that Extend Half-life of Factor Concentrates

Novel Technologies that Extend Half-life of Factor Concentrates (continued)

Novel Technologies that Extend Half-life of Factor Concentrates (continued)

Novel Technologies that Extend Half-life of Factor Concentrates (continued)

Novel Pipeline Therapies—Gene Therapy

Novel Pipeline Therapies—RNA Interference

Novel Pipeline Therapies—Tissue Factor Pathway Inhibitor

Haemophilia A Therapeutics (FVIII) Market—Timeline of Key Events

Haemophilia B Therapeutics (FIX) Market—Timeline of Key Events

Inhibitors (Bypassing Agents) (FVIIa) Market—Timeline of Key Events

Leading Big Pharma Companies—SWOT Analysis Bayer

Leading Big Pharma Companies—SWOT Analysis Baxter

Leading Big Pharma Companies—SWOT Analysis Novo Nordisk

Leading Big Pharma Companies—SWOT Analysis Pfizer

Key Companies to Watch—SWOT Analysis Biogen Idec

Key Companies to Watch—SWOT Analysis CSL Behring

Comparative Product Analysis of Key Market Participants

Conclusions and Recommendations

Legal Disclaimer

List of Abbreviations

The Frost & Sullivan Story

Value Proposition

Global Perspective

Industry Convergence

360º Research Perspective

Implementation Excellence

Our Blue Ocean Strategy